TY - JOUR
T1 - Combination of converting enzyme inhibitor with diuretic for the treatment of hypertension
AU - Townsend, Raymond R.
AU - Holland, O. Bryan
PY - 1990/6
Y1 - 1990/6
N2 - In recent years there has been increased discussion about goals of antihypertensive therapy other than blood pressure reduction. The development of angiotensin-converting enzyme inhibitors has provided a class of drugs with a very low side-effect profile. However, single-drug therapy is effective in only about half of hypertensive patients. In the past, diuretics have traditionally been used as the initial or second antihypertensive. Increasingly, diuretic therapy is being avoided, and other antihypertensive combinations are being used. In controlled trials, combination converting enzyme inhibitor-diuretic therapy is effective in about 85% of patients. This synergistic combination allows the diuretic dose to be reduced so that the adverse effects and metabolic complications are minimized. At this time, the combination of converting enzyme inhibitor and diuretic provides an ideal choice in terms of efficacy, compliance, side effects, and cost.
AB - In recent years there has been increased discussion about goals of antihypertensive therapy other than blood pressure reduction. The development of angiotensin-converting enzyme inhibitors has provided a class of drugs with a very low side-effect profile. However, single-drug therapy is effective in only about half of hypertensive patients. In the past, diuretics have traditionally been used as the initial or second antihypertensive. Increasingly, diuretic therapy is being avoided, and other antihypertensive combinations are being used. In controlled trials, combination converting enzyme inhibitor-diuretic therapy is effective in about 85% of patients. This synergistic combination allows the diuretic dose to be reduced so that the adverse effects and metabolic complications are minimized. At this time, the combination of converting enzyme inhibitor and diuretic provides an ideal choice in terms of efficacy, compliance, side effects, and cost.
UR - http://www.scopus.com/inward/record.url?scp=0025353862&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025353862&partnerID=8YFLogxK
M3 - Article
C2 - 2191634
AN - SCOPUS:0025353862
SN - 0003-9926
VL - 150
SP - 1175
EP - 1183
JO - Archives of Internal Medicine
JF - Archives of Internal Medicine
IS - 6
ER -